AstraZeneca has posted a profit after tax of $1.37bn for the third quarter (Q3) of 2023, compared with $1.64bn in the same quarter of the previous year, indicating a decline of 16% on an actual basis.

For the quarter ended 30 September 2023, the company saw a 17% rise in gross profit to $9.39bn from $8.0bn in Q3 2022.

The earnings per share (EPS) on a reported basis was $0.89 compared with $1.06 in the third quarter of 2022, signifying a 16% drop. 

The company’s earnings before interest, taxes, depreciation, and amortisation rose by 25% to $3.23bn from 2.57 in Q3 2022.

Revenue was $11.49bn versus $10.98bn in the third quarter of 2022, up 5% on an actual basis.  

In the oncology therapy area, the company’s revenues stood at $4.66bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Revenues were $2.68bn in cardiovascular, renal and metabolism areas, $1.54bn in respiratory and immunology areas, $312m in vaccines and immune therapies, and $1.97bn in rare diseases.

Product sales were reported at $11.01bn from $10.59bn in Q3 2022, indicating a growth of 4%.

AstraZeneca CEO Pascal Soriot stated: “Our company continued its strong growth trajectory in the third quarter with total revenue from our non‑Covid-19 medicines up 13% compared to last year. 

“Given the momentum in the year to date, we have increased our full-year guidance for total revenue excluding Covid medicines, as well as for core EPS.”

In early November 2023, the company entered a partnership with Eccogene for ECC5004, a small molecule GLP-1 agonist.